Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 7/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | MC4R | P32245 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3839500 | 1.00 | SLC18A3 (0.44) | SLC18A3ALDH1A1TSHRCYP1A2CHRM2 | |
| SCHEMBL3839504 | 1.00 | SLC18A3 (0.44) | SLC18A3ALDH1A1TSHRCYP1A2CHRM2 | |
| SCHEMBL5422025 | 0.96 | ALDH1A1 (0.46) | SLC18A3ALDH1A1TSHRCYP1A2CHRM2 | |
| SCHEMBL20703762 | 0.96 | ALDH1A1 (0.46) | SLC18A3ALDH1A1TSHRCYP1A2CHRM2 | |
| SCHEMBL8829142 | 0.96 | ALDH1A1 (0.46) | SLC18A3ALDH1A1TSHRCYP1A2CHRM2 | |
| SCHEMBL5422028 | 0.96 | ALDH1A1 (0.46) | SLC18A3ALDH1A1TSHRCYP1A2CHRM2 | |
| SCHEMBL250436 | 0.89 | SLC18A3 (0.46) | SLC18A3ALDH1A1TSHRCYP1A2CHRM2 | |
| SCHEMBL12446288 | 0.89 | SLC18A3 (0.46) | SLC18A3ALDH1A1TSHRCYP1A2CHRM2 | |
| SCHEMBL17226159 | 0.89 | SLC18A3 (0.46) | SLC18A3ALDH1A1TSHRCYP1A2CHRM2 | |
| SCHEMBL10048505 | 0.89 | SLC18A3 (0.46) | SLC18A3ALDH1A1TSHRCYP1A2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3388433-B1 | PHTHALAZINE DERIVATIVES, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI SIMR BIOTECH CO LTD (CN) | 2023-08-30 | — | — | EP | disclosed |
| EP-3388433-B1 | PHTHALAZINE DERIVATIVES, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI SIMR BIOTECH CO LTD (CN) | 2023-08-30 | — | — | EP | disclosed |
| US-11220503-B2 | Phthalazine derivatives, preparation method, pharmaceutical composition and usage thereof | SHANGHAI SIMR BIOTECH CO., LTD. (CN) | 2022-01-11 | — | — | US | disclosed |
| US-11220503-B2 | Phthalazine derivatives, preparation method, pharmaceutical composition and usage thereof | SHANGHAI SIMR BIOTECH CO., LTD. (CN) | 2022-01-11 | — | — | US | disclosed |
| US-20200165253-A1 | Phthalazine Derivatives, Preparation Method, Pharmaceutical Composition and Usage Thereof | SHANGHAI SIMRD BIOTECHNOLOGY. CO., LTD. (CN) | 2020-05-28 | — | — | US | disclosed |
| US-20200165253-A1 | Phthalazine Derivatives, Preparation Method, Pharmaceutical Composition and Usage Thereof | SHANGHAI SIMRD BIOTECHNOLOGY. CO., LTD. (CN) | 2020-05-28 | — | — | US | disclosed |
| WO-2017097217-A1 | PHTHALAZINE DERIVATIVES, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 上海赛默罗生物科技有限公司 | 2017-06-15 | — | — | WO | disclosed |
| EP-1457495-A1 | Adenosine A1 receptor agonists | GLAXO GROUP LIMITED (GB) | 2004-09-15 | — | — | EP | disclosed |
| EP-1030857-B1 | ADENOSINE A1 RECEPTOR AGONISTS | GLAXO GROUP LTD (GB) | 2004-08-18 | — | — | EP | disclosed |
| US-6455510-B1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2002-09-24 | — | — | US | disclosed |
| US-6407076-B1 | ANTIISCHEMIC, ANTILIPOLYTIC, ANTICONVULSANT AND HYPOTENSIVE AGENTS; CARDIOVASCULAR AND NERVOUS SYSTEM DISORDERS; ATHEROSCLEROSIS | SMITHKLINE BEECHAM CORPORATION | 2002-06-18 | — | — | US | disclosed |
| EP-1030857-A2 | ADENOSINE A1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2000-08-30 | — | — | EP | disclosed |
| EP-1027363-A2 | ADENOSINE A1-RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2000-08-16 | — | — | EP | disclosed |
| WO-1999024450-A2 | ADENSINE A1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 1999-05-20 | — | — | WO | disclosed |
| WO-1999024449-A2 | ADENOSINE A1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 1999-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11220503-B2 | Phthalazine derivatives, preparation method, pharmaceutical composition and usage thereof | GABRA5, CYP3A5, GABRA1 | SLC18A3 1112/4885ALDH1A1 1006/4885TSHR 389/4885 |
| US-20200165253-A1 | Phthalazine Derivatives, Preparation Method, Pharmaceutical Composition and Usage Thereof | GABRA5, CYP3A5, GABRA1 | SLC18A3 1112/4885ALDH1A1 1006/4885TSHR 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.